idiopathic multicentric Castleman disease
Rare disease · 2021–2021
2decisions
1medicine
2carried consumer input
11individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| siltuximab Treatment of patients with idiopathic multicentric Castleman disease (iMCD) who are HIV negative and HHV-8 negative. | Jul 2021 | Not recommended | 11 individuals Myeloma Australia |
| siltuximab Treatment of idiopathic multicentric Castleman disease (iMCD) in HIV-negative and HHV-8-negative patients. | Nov 2021 | Recommended with restriction | input received |
Who spoke
Myeloma Australia
What the PBS pays
$5M in government benefit over 2024–25, across 843 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| siltuximab | $4.8M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 2 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.